Viscardi Gabrielle, Back Songhee, Ahmed Amna, Yang Shuting, Mejia Sonia Blanco, Zurbau Andreea, Khan Tauseef A, Selk Amanda, Messina Mark, Kendall Cyril Wc, Jenkins David Ja, Sievenpiper John L, Chiavaroli Laura
Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada.
Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Adv Nutr. 2025 Jan;16(1):100327. doi: 10.1016/j.advnut.2024.100327. Epub 2024 Oct 20.
Despite recommendations to increase plant food consumption for public and planetary health and the role that soy foods can play in plant-predominant diets, controversies around the effects of soy foods, especially soy isoflavones, are a barrier to their intake. Given their cardioprotective effects and ability to alleviate menopausal symptoms, addressing these concerns is particularly relevant to women. This systematic review and meta-analysis of randomized controlled trials aimed to determine the effect of soy isoflavones on measures of estrogenicity in postmenopausal women. MEDLINE, Embase, and Cochrane Library were searched through August 2024 for randomized trials ≥3-mo investigating soy isoflavones compared with non-isoflavone controls in postmenopausal women. Outcomes included endometrial thickness (ET), vaginal maturation index (VMI), follicle-stimulating hormone (FSH), and estradiol. Independent authors extracted data and assessed risk of bias. Grading of Recommendations, Assessment, Development and Evaluation was used to assess certainty of evidence. We included 40 trials (52 trial comparisons, n = 3285) assessing the effect of a median reported dose of 75 mg/d of soy isoflavones in substitution for non-isoflavone controls over a median of 24 wk. Soy isoflavones had no statistically significant effect on any measure of estrogenicity; ET [mean difference, -0.22 mm (95% confidence interval, -0.45, 0.01 mm), P = 0.059], VMI [2.31 (-2.14, 6.75), P = 0.310], FSH [-0.02 IU/L (-2.39, 2.35 IU/L), P = 0.987], and estradiol [1.61 pmol/L (-1.17, 4.38 pmol/L), P = 0.256]. The certainty of evidence was high to moderate for all outcomes. Current evidence suggests that soy isoflavones do not exhibit estrogenic effects compared with non-isoflavone controls on 4 measures of estrogenicity in postmenopausal women. This synthesis supports that soy isoflavones likely act as selective estrogen receptor modulators, differing clinically from the hormone estrogen. Addressing public health concerns may promote soy foods as high-quality plant protein sources with low environmental impact and cost, particularly benefiting postmenopausal women and aligning with sustainable dietary patterns and guidelines. This study was registered in PROSPERO as CRD42023439239.
尽管有建议为了公众健康和地球健康增加植物性食物的摄入量,且大豆食品在以植物为主的饮食中可以发挥作用,但围绕大豆食品(尤其是大豆异黄酮)的影响存在争议,这成为人们摄入大豆食品的障碍。鉴于其对心脏的保护作用以及缓解更年期症状的能力,解决这些担忧对女性尤为重要。这项对随机对照试验的系统评价和荟萃分析旨在确定大豆异黄酮对绝经后女性雌激素活性指标的影响。检索了MEDLINE、Embase和Cochrane图书馆截至2024年8月的随机试验,这些试验对绝经后女性中大豆异黄酮与非异黄酮对照进行了≥3个月的研究。结局指标包括子宫内膜厚度(ET)、阴道成熟指数(VMI)、促卵泡生成素(FSH)和雌二醇。独立作者提取数据并评估偏倚风险。使用推荐分级、评估、制定与评价(GRADE)来评估证据的确定性。我们纳入了40项试验(52次试验比较,n = 3285),评估了中位报告剂量为75 mg/d的大豆异黄酮替代非异黄酮对照在中位24周内的效果。大豆异黄酮对任何雌激素活性指标均无统计学显著影响;ET[平均差,-0.22 mm(95%置信区间,-0.45,0.01 mm),P = 0.059],VMI[2.31(-2.14,6.75),P = 0.310],FSH[-0.02 IU/L(-2.39,2.35 IU/L),P = 0.987],以及雌二醇[1.61 pmol/L(-1.17,4.38 pmol/L),P = 0.256]。所有结局的证据确定性为高到中等。当前证据表明,与非异黄酮对照相比,大豆异黄酮在绝经后女性的4项雌激素活性指标上未表现出雌激素作用。这一综合分析支持大豆异黄酮可能作为选择性雌激素受体调节剂发挥作用,在临床上与激素雌激素不同。解决公共卫生方面的担忧可能会促进将大豆食品作为对环境影响小且成本低的优质植物蛋白来源,尤其使绝经后女性受益,并符合可持续饮食模式和指南。本研究已在国际前瞻性注册系统(PROSPERO)注册,注册号为CRD42023439239。